Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
National Institutes of Health (NIH)
Funding amount is not limited but must reflect the actual needs of the proposed project.
Maximum project period is five years.
To support research elucidating how HIV-induced immunometabolic alterations impact immune responses and increase risks for TB or HBV.
Aims to define how HIV-driven alterations affect immune cell regulation and disease progression.
Public and private nonprofit institutions, individuals, and various educational and governmental organizations.
Research teams and communities affected by HIV, TB, and HBV.
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, local and state governments, and tribal governments.
Nonprofits with and without 501(c)(3) IRS status are eligible.
Open to U.S. and non-domestic (foreign) entities.
Non-domestic components of U.S. organizations are also eligible.
Research must focus on HIV immunometabolism and its impact on TB or HBV.
Applications must be hypothesis-driven and can include basic, preclinical, and translational studies.
Application budgets are not limited but must reflect the actual needs of the proposed project.
No cost-sharing is required.
Applications are due by 5:00 PM local time of the applicant organization.
Key dates include opening date on April 07, 2025, and closing date on January 07, 2028.
Applicants may submit more than one application provided each is scientifically distinct.
The NIH will not accept duplicate or overlapping applications under review at the same time.
Applications must follow the instructions in the Research Application Guide.
Specific forms include SF424(R&R) and PHS 398.
Applications will be evaluated based on significance, innovation, approach, investigator expertise, and environment.
Applications will undergo peer review and will receive a written critique.
Funding decisions will consider scientific merit and relevance to program priorities.
Priority will be given to applications demonstrating a strong scientific impact and relevance to NIH priorities.
Applications must not propose clinical trials.
Interdisciplinary teams are encouraged.
Applications that do not comply with submission guidelines may be delayed or rejected.
Utilization of existing clinical samples and novel AI approaches is encouraged.
Strong preliminary data and interdisciplinary collaboration may enhance competitiveness.
Demonstrating a clear understanding of immunometabolic mechanisms related to HIV.
Submitting applications that overlap significantly with previously submitted proposals.
Engage with collaborators early to strengthen the application.
Highlight unique methodologies and potential for impactful discoveries.